Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

被引：22

作者：

Liu, Shuna ^{[1
,2
]}

Wu, Ming ^{[1
,2
]}

Wang, Fang ^{[1
,2
]}

机构：

[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Lab Med, Nanjing 210029, Peoples R China

[2] Natl Key Clin Dept Lab Med, Nanjing 210029, Peoples R China

来源：

JOURNAL OF CANCER | 2021年 / 12卷 / 13期

关键词：

ovarian cancer; prognostic factor; biomarker; TUMOR-INFILTRATING LYMPHOCYTES; EPITHELIAL-MESENCHYMAL TRANSITION; PLATINUM-BASED CHEMOTHERAPY; PD-L1; EXPRESSION; POOR-PROGNOSIS; THERAPEUTIC TARGET; PREOPERATIVE NEUTROPHIL; INVESTIGATIONAL AURORA; CELL-PROLIFERATION; CLINICAL-OUTCOMES;

D O I：

10.7150/jca.47695

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is a serious threat to women's health; its early diagnosis rate is low and prone to metastasis and recurrence. The current conventional treatment for ovarian cancer is a combination of platinum and paclitaxel chemotherapy based on surgery. The recurrence and progression of ovarian cancer with poor prognosis is a major challenge in treatment. With rapid advances in technology, understanding of the molecular pathways involved in ovarian cancer recurrence and progression has increased, biomarker-guided treatment options can greatly improve the prognosis of patients. This review systematically discusses and summarizes existing and new information on prognostic factors and biomarkers of ovarian cancer, which is expected to improve the clinical management of patients and lead to effective personalized treatment.

引用

页码：3976 / 3996

页数：21

共 352 条

[1] Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma [J].

Abou-Taleb, Hisham ;

Yamaguchi, Ken ;

Matsumura, Noriomi ;

Murakami, Ryusuke ;

Nakai, Hidekatsu ;

Higasa, Koichiro ;

Amano, Yasuaki ;

Abiko, Kaoru ;

Yoshioka, Yumiko ;

Hamanishi, Junzo ;

Koshiyama, Masafumi ;

Baba, Tsukasa ;

Yamada, Ryo ;

Matsuda, Fumihiko ;

Konishi, Ikuo ;

Mandai, Masaki .

ONCOTARGET, 2016, 7 (34) :54758-54770

[2]

Ai H, 2018, EUR REV MED PHARMACO, V22, P5836, DOI 10.26355/eurrev_201809_15910

[3] Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers [J].

Amano, Tsukuru ;

Chano, Tokuhiro ;

Isono, Takahiro ;

Kimura, Fuminori ;

Kushima, Ryoji ;

Murakami, Takashi .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)

[4] CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis [J].

Ayhan, Ayse ;

Kuhn, Elisabetta ;

Wu, Ren-Chin ;

Ogawa, Hiroshi ;

Bahadirli-Talbott, Ash ;

Mao, Tsui-Lien ;

Sugimura, Haruhiko ;

Shih, Ie-Ming ;

Wang, Tian-Li .

MODERN PATHOLOGY, 2017, 30 (02) :297-303

[5] Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer [J].

Ayub, Tiyasha H. ;

Keyver-Paik, Mignon-Denise ;

Debald, Manuel ;

Rostamzadeh, Babak ;

Thiesler, Thore ;

Schroeder, Lars ;

Barchet, Winfried ;

Abramian, Alina ;

Kaiser, Christina ;

Kristiansen, Glen ;

Kuhn, Walther ;

Kuebler, Kirsten .

ONCOTARGET, 2015, 6 (18) :16437-16448

[6] Treatment options for ovarian cancer [J].

Baker, VV .

CLINICAL OBSTETRICS AND GYNECOLOGY, 2001, 44 (03) :522-530

[7] Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression [J].

Bartling, Toni R. ;

Subbaram, Sita ;

Clark, Ryan R. ;

Chandrasekaran, Akshaya ;

Kar, Supriya ;

Melendez, J. Andres .

FREE RADICAL BIOLOGY AND MEDICINE, 2014, 74 :99-107

[8] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].

BAST, RC ;

FEENEY, M ;

LAZARUS, H ;

NADLER, LM ;

COLVIN, RB ;

KNAPP, RC .

JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337

[9] Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors [J].

Beeghly-Fadiel, Alicia ;

Wilson, Andrew J. ;

Keene, Spencer ;

El Ramahi, Meral ;

Xu, Shu ;

Marnett, Lawrence J. ;

Fadare, Oluwole ;

Crispens, Marta A. ;

Khabele, Dineo .

JOURNAL OF OVARIAN RESEARCH, 2018, 11

[10] Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J].

Bell, Jeffrey ;

Brady, Mark F. ;

Young, Robert C. ;

Lage, Janice ;

Walker, Joan L. ;

Look, Katherine Y. ;

Rose, G. Scott ;

Spirtos, Nick M. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :432-439

← 1 2 3 4 5 6 7 8 9 10 →